A single-arm, open-label clinical study of irinotecan liposome combined with capecitabine, bevacizumab and camrelizumab as second-line or above treatment for patients with metastatic colorectal cancer, aiming to evaluate the efficacy and safety of irinotecan liposome combined with capecitabine, bevacizumab and camrelizumab as second-line or above treatment for patients with metastatic colorectal cancer The medication regimen is irinotecan liposome (II) + capecitabine + bevacizumab + camrelizumab until disease progression or intolerable toxicity.
Patients pathologically diagnosed with colorectal cancer;
Received systemic treatment on the first line;
Age: 18 to 75 years old, gender not limited.
There must be at least one measurable lesion as the target lesion (in accordance with the RECIST v1.1 standard);
Patients with wild-type RAS and BRAF, whose primary lesion is located in the left colorectal tract, but who have not received cetuximab as the first-line treatment
Patients with advanced colorectal cancer who have MSI-H or dMMR
Those with a history of other malignant diseases in the last five years, except for cured skin cancer and cervical carcinoma in situ
For patients with a history of uncontrolled epilepsy, central nervous system diseases or mental disorders, the researcher will determine that the clinical severity may prevent them from signing the informed consent form or affect their compliance with oral medication